Avanos Medical, Inc. Stock News

Avanos Medical is deeply undervalued, with strong international expansion, aggressive M&A strategy, and a new CFO poised to drive inorganic growth. AVNS operates in high-growth markets, maintains a solid balance sheet with low debt, and trades at a significant discount to sector peers on earnings and book value. Ongoing transformation, divestitures, and stock repurchases are expected to enhance...

ALPHARETTA, Ga. , Sept. 15, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS), a leading medical technology company, today announced the acquisition of Nexus Medical, LLC, a privately held medical device company based in Lenexa, Kansas.

Avanos Medical, Inc. appears deeply undervalued after years of restructuring, with a potential stabilization in sales and earnings projected for 2025. Recent tariff impacts and lowered guidance seem fully priced in, setting the stage for upside surprises and a share price rally into 2026. Insider buying and improving technical indicators suggest a sea change for investor confidence could be next.

Avanos Medical, Inc. (NYSE:AVNS ) Q2 2025 Earnings Conference Call August 5, 2025 9:00 AM ET Company Participants David C. Pacitti - Chief Executive Officer Jason M.

Avanos Medical (AVNS) Q2 Revenue Up 2%

ALPHARETTA, Ga. , Aug. 5, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS), a leading medical technology company, today announced the appointment of Scott Galovan as its new senior vice president, chief financial officer, effective Aug. 1, 2025.

ALPHARETTA, Ga. , Aug. 5, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported second quarter 2025 financial results.

ALPHARETTA, Ga. , July 31, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS), announced today the divestiture of its Hyaluronic Acid (HA) product line to Channel-Markers Medical, LLC (CMM), a privately held company based in Raleigh, NC.